<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D1633440-BB08-4BAD-962E-17B6726E0EB7"><gtr:id>D1633440-BB08-4BAD-962E-17B6726E0EB7</gtr:id><gtr:name>OrganDot</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C9A0A2C8-9B30-4BA2-9843-A962C2D56FC2"><gtr:id>C9A0A2C8-9B30-4BA2-9843-A962C2D56FC2</gtr:id><gtr:name>Asterand</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Medical and Human Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name><gtr:address><gtr:line1>BBSRC</gtr:line1><gtr:line2>Polaris House</gtr:line2><gtr:line3>North Star Avenue</gtr:line3><gtr:line4>Swindon</gtr:line4><gtr:postCode>SN2 1UH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1633440-BB08-4BAD-962E-17B6726E0EB7"><gtr:id>D1633440-BB08-4BAD-962E-17B6726E0EB7</gtr:id><gtr:name>OrganDot</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C9A0A2C8-9B30-4BA2-9843-A962C2D56FC2"><gtr:id>C9A0A2C8-9B30-4BA2-9843-A962C2D56FC2</gtr:id><gtr:name>Asterand</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/B7353A60-F025-491A-992E-26913B506DF2"><gtr:id>B7353A60-F025-491A-992E-26913B506DF2</gtr:id><gtr:name>Capsant Neurotechnologies Limited</gtr:name><gtr:address><gtr:line1>Unit 2</gtr:line1><gtr:line2>Winchester Hill</gtr:line2><gtr:line4>Romsey</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO51 7UT</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1D24F09F-3905-46D5-95D6-E8E49AFF185E"><gtr:id>1D24F09F-3905-46D5-95D6-E8E49AFF185E</gtr:id><gtr:firstName>William</gtr:firstName><gtr:otherNames>Peter</gtr:otherNames><gtr:surname>Gray</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/21B7B005-C2AE-4BDF-B793-BCD87266DB03"><gtr:id>21B7B005-C2AE-4BDF-B793-BCD87266DB03</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Ian</gtr:otherNames><gtr:surname>Wilson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/CD3F1521-A302-4D7A-B7D4-6BF3276BF4CC"><gtr:id>CD3F1521-A302-4D7A-B7D4-6BF3276BF4CC</gtr:id><gtr:firstName>Neil</gtr:firstName><gtr:otherNames>A</gtr:otherNames><gtr:surname>Hanley</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=DT%2FE005039%2F2"><gtr:id>3A1EECA4-3F64-43EF-9FFD-59C942104F8A</gtr:id><gtr:title>Chameleon Spots</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>DT/E005039/2</gtr:grantReference><gtr:abstractText>The team will translate basic laboratory research using valuable human cell types and novel culture methodology called 'Hi-spot' into biopharmaceutical products. Hi-spot permits cell / tissue culture on small membranes at the air-liquid interface permitting 3D structural qualities to cultures and fostering more physiological cell-cell interactions. The underlying rationale is that this environment generates closer mimicry of in vivo conditions within the in vitro culture setting. In turn, this improvement fosters more robust, representative technology to take into the biopharmaceutical workplace for toxicology screening and drug discovery. By itself, this represents a significant advance. The second distinctive quality to our application comes from the highly specialist cells and tissues that we will bring to the Hi-spot technology platform. The consortium that we have established brings expertise in human stem cell and primary progenitor cell-types from the academic sector to the University of Southampton spin-out company Capsant Technologies (http://www.capsant.co.uk/). The cell-types are of fundamental interest to industry focused on drug toxicity and drug discovery. They are discussed in the following work packages that comprise our application. 1. Primary human fetal cells. The Hanley and Wilson laboratories will establish 'Hi-spot' culture methodology from the following human primary fetal cell-types: a) neuroprogenitors / differentiated progeny; b) cardiomyocytes; c) hepatocytes; d) and pancreatic progenitors / beta cells. The first three cell types are obvious targets for toxicology studies. The latter cell-type is of great interest for drug discovery of novel insulin secretagogues. 2. Human embryonic stem (ES) cells. The Minger laboratory will parallel Work Package 1 with differentiated human ES cells. There is great interest in ES cells for toxicology screening; however, one of the main questions hanging over their application is how representative are their differentiated progeny compared to normal cell-types. This application offers a rare opportunity to put them up against normal human primary cell-types. 3. Human adult CNS stem cells. The Gray lab has privileged access to rare populations of adult hippocampal neural cells that retain proliferative capacity and act as stem cells. Establishing these cells in culture and applying them to Hi-spot technology will be a significant step in neurotoxicology screening. 4. Work package 4 will run in parallel to those above and provide validation and exploitation of the academic laboratory research. Fluorescent biochemical and electrophysiological approaches are already in place on microelectrode arrays. This work package will also take the expertise into 96- and 384-well format systems. 5. The final work package will begin the process of taking our intellectual property and products to the market place via commercial assessment and a dissemination programme for academic and commercial users. Taken together, these approaches provide a cohesive, lucid strategy to take privileged expertise for improving human culture models into the market place for advances in commercial drug toxicology screening and drug discovery.</gtr:abstractText><gtr:fund><gtr:end>2011-08-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2009-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>429779</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>EPSRC DTI grant</gtr:description><gtr:id>D69D9843-6029-406F-82ED-4A79BB755C0E</gtr:id><gtr:impact>With OrganDot, the Hepatology paper, Rowe et al.
With Asterand, the follow on TSB funding.</gtr:impact><gtr:partnerContribution>Industry input into the experiments and in reagents</gtr:partnerContribution><gtr:piContribution>We have conducted basic lab research that led to an EPSRC Acceleration award on Concept &amp;amp; Feasibility, which in turn has led to Asterand being awarded a Concept &amp;amp; Feasibility award from TSB.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Asterand</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>EPSRC DTI grant</gtr:description><gtr:id>5EA6166D-66EE-4EED-8AC3-402B187203A5</gtr:id><gtr:impact>With OrganDot, the Hepatology paper, Rowe et al.
With Asterand, the follow on TSB funding.</gtr:impact><gtr:partnerContribution>Industry input into the experiments and in reagents</gtr:partnerContribution><gtr:piContribution>We have conducted basic lab research that led to an EPSRC Acceleration award on Concept &amp;amp; Feasibility, which in turn has led to Asterand being awarded a Concept &amp;amp; Feasibility award from TSB.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>OrganDot</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>EPSRC DTI grant</gtr:description><gtr:id>870AE93E-878F-4098-89C6-70E00BDFF6AA</gtr:id><gtr:impact>With OrganDot, the Hepatology paper, Rowe et al.
With Asterand, the follow on TSB funding.</gtr:impact><gtr:partnerContribution>Industry input into the experiments and in reagents</gtr:partnerContribution><gtr:piContribution>We have conducted basic lab research that led to an EPSRC Acceleration award on Concept &amp;amp; Feasibility, which in turn has led to Asterand being awarded a Concept &amp;amp; Feasibility award from TSB.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Asterand</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Asterand EPSRC KTP award</gtr:description><gtr:id>52E46BEF-B020-4A17-AA0D-ECD30DAAA60C</gtr:id><gtr:impact>Commercial activity from Asterand</gtr:impact><gtr:partnerContribution>They were the commercial partners</gtr:partnerContribution><gtr:piContribution>This award built on the Chameleon spots grant and tested commercial proof of principle with Asterand who licensed the technology.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Advancing the Development and Application of Non-Animal Technologies Feasibility Studies</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>Technology Strategy Board (TSB)</gtr:fundingOrg><gtr:fundingRef>TSB grant project 131732</gtr:fundingRef><gtr:id>D13D328A-0C03-4A15-A93C-890122E507E9</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2014-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Hepatology paper, Rowe et al, has disseminated information to the field internationally. Uptake in commercialisation by Asterand. We have just completed Innovate UK non-animal technologies funding in partnership with Asterand.</gtr:description><gtr:firstYearOfImpact>2012</gtr:firstYearOfImpact><gtr:id>7AC5398E-202B-42A3-8C9E-E51AD17F19A1</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Improved 3D culture at air-liquid interface.</gtr:description><gtr:id>0E478993-7084-49F9-8C5F-C7B0DD59C4A3</gtr:id><gtr:impact>It is commercially available through Asterand.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Licensed technology to Asterand for the 3D culture</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Air-liquid interface culture</gtr:description><gtr:id>8DFE4013-80EC-4F49-8FDF-0E9A910E50F2</gtr:id><gtr:impact>Hepatology paper in 2013, Rowe et al.
The methodology is now transferred to Asterand Ltd.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Hepatocyte culture</gtr:title><gtr:type>Biological samples</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842115/</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B469C4DA-7AC3-4B4B-9B1C-E173703E9216"><gtr:id>B469C4DA-7AC3-4B4B-9B1C-E173703E9216</gtr:id><gtr:title>Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening.</gtr:title><gtr:parentPublicationTitle>Stem cell research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f9ba1569cd98c74f7d57fc9f3abdeef5"><gtr:id>f9ba1569cd98c74f7d57fc9f3abdeef5</gtr:id><gtr:otherNames>Baxter MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1873-5061</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/51F172D4-1883-46D8-994F-A2B4BB3D898B"><gtr:id>51F172D4-1883-46D8-994F-A2B4BB3D898B</gtr:id><gtr:title>Proteome-wide analyses of human hepatocytes during differentiation and dedifferentiation.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7fcf6319aaaa051e71570ab1a5fbb0d4"><gtr:id>7fcf6319aaaa051e71570ab1a5fbb0d4</gtr:id><gtr:otherNames>Rowe C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E5880510-A265-4AF5-B901-A6CB39C91525"><gtr:id>E5880510-A265-4AF5-B901-A6CB39C91525</gtr:id><gtr:title>PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/55f6c6d440adbbc77668a052f9c0d839"><gtr:id>55f6c6d440adbbc77668a052f9c0d839</gtr:id><gtr:otherNames>Martin K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FA5F69C2-D00A-4B18-9764-C7C015123764"><gtr:id>FA5F69C2-D00A-4B18-9764-C7C015123764</gtr:id><gtr:title>The long-term survival of in vitro engineered nervous tissue derived from the specific neural differentiation of mouse embryonic stem cells.</gtr:title><gtr:parentPublicationTitle>Biomaterials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/702fc6231ccc8b58dcf74b567552a724"><gtr:id>702fc6231ccc8b58dcf74b567552a724</gtr:id><gtr:otherNames>Dubois-Dauphin ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0142-9612</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/02D3DCF6-3FB3-41EE-B8BA-6479F86B4747"><gtr:id>02D3DCF6-3FB3-41EE-B8BA-6479F86B4747</gtr:id><gtr:title>Stem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injury.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7f098469dc1dbb18dc75ff4bb9372c1b"><gtr:id>7f098469dc1dbb18dc75ff4bb9372c1b</gtr:id><gtr:otherNames>Goldring C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/602D2C0B-8361-4C27-B312-C17488A065E0"><gtr:id>602D2C0B-8361-4C27-B312-C17488A065E0</gtr:id><gtr:title>MicroRNA-122: a novel hepatocyte-enriched in vitro marker of drug-induced cellular toxicity.</gtr:title><gtr:parentPublicationTitle>Toxicological sciences : an official journal of the Society of Toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e8f8b5adafdd370252c7fc6d85d8b907"><gtr:id>e8f8b5adafdd370252c7fc6d85d8b907</gtr:id><gtr:otherNames>Kia R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1096-0929</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B2975430-963B-40F8-BE10-26A62DEC6B77"><gtr:id>B2975430-963B-40F8-BE10-26A62DEC6B77</gtr:id><gtr:title>Phenotypic and functional analyses show stem cell-derived hepatocyte-like cells better mimic fetal rather than adult hepatocytes.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/86657e337abedb83adf26de5d8f16dcd"><gtr:id>86657e337abedb83adf26de5d8f16dcd</gtr:id><gtr:otherNames>Baxter M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1410E5CD-0ECC-4E99-B064-C8A6F7CDAA8A"><gtr:id>1410E5CD-0ECC-4E99-B064-C8A6F7CDAA8A</gtr:id><gtr:title>Maturation of induced pluripotent stem cell derived hepatocytes by 3D-culture.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/69b910fd75a5f4df405412df66812851"><gtr:id>69b910fd75a5f4df405412df66812851</gtr:id><gtr:otherNames>Gieseck RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">DT/E005039/2</gtr:identifier></gtr:identifiers><gtr:projectHierarchy><gtr:parents><gtr:parent><gtr:id>FA2F44F5-BCB3-4DF7-8F08-7730EC607A89</gtr:id><gtr:grantRef>DT/E005039/1</gtr:grantRef><gtr:amount>808154.35</gtr:amount><gtr:start>2007-04-01</gtr:start><gtr:end>2008-08-31</gtr:end><gtr:children><gtr:child rel="Transfer"><gtr:id>3A1EECA4-3F64-43EF-9FFD-59C942104F8A</gtr:id><gtr:grantRef>DT/E005039/2</gtr:grantRef><gtr:amount>429779.59</gtr:amount><gtr:start>2009-09-01</gtr:start><gtr:end>2011-08-31</gtr:end><gtr:children/></gtr:child></gtr:children></gtr:parent></gtr:parents></gtr:projectHierarchy><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>6723A70B-A523-40AB-9740-B6AD2A0677B7</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Medical &amp; health interface</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>99E0B904-CAB5-4511-AFB3-AA6D2B171F97</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Process engineering</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>9C387DA5-CD5F-43E4-AA74-82CBF4DB6617</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Bioprocess Engineering</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>195B48B4-2BC5-4DEB-BA1A-323A90D8730D</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Tissue engineering</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>